Projects per year
Personal profile
Research interests
Research Expertise:
Organic & Medicinal Chemistry | Organoboron Chemistry | Alternate Energy Materials
Medicinal Chemistry: We have been developing novel aza- and bora-heterocyclic compounds and betulin-based natural product derivatives as anti-cancer agents. In collaboration with Rowan School of Osteopathic Medicine, we have also identified few Withaferin-serotonin conjugates as potential therapeutic options for the treatment of Alzheimers’ Disease.
Value Added Chemicals from Biomass: Recent efforts in this area have included the development of new protocols for the effective conversion of biomass derived cellulosic materials into chemicals such as hydroxymethyl furfural and furan dicarboxylic acid for applications as bio-based polymers.
Honors and Awards:
Rowan University Wall of Fame Teaching Award, 2013, 2016
Eli Lilly International Graduate Scholar, 2000-2005, Purdue University
Member of:
American Chemical Society (www.acs.org)
Education/Academic qualification
Doctor of Philosophy, doctorate
Bachelor of Science, Bachelor, Pondicherry University
Master of Science, Master, University of Hyderabad
Fingerprint
Dive into the research topics where Subash Jonnalagadda is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Projects
-
Development of Novel Small Molecules as Potential Anti-Cancer Agents
1/1/15 → 12/31/20
Project: Research project
-
Research and Development of Topical and Intravenous Formulations
6/1/16 → 5/31/17
Project: Other project
-
-
Preparation and Purification of Biologically Relevant Natural Products
Rosenberg Integrative Cancer Treatment and Research Institute
1/1/15 → 12/21/15
Project: Research project
Research Output
-
Nucleic acid delivery with α-tocopherol-polyethyleneimine-polyethylene glycol nanocarrier system
Nawshad Hossian, A. K. M., Jois, S. D., Jonnalagadda, S. C. & Mattheolabakis, G., 2020, In: International Journal of Nanomedicine. 15, p. 6689-6703 15 p.Research output: Contribution to journal › Article › peer-review
Open Access -
Old drugs, new uses: Drug repurposing in hematological malignancies
Kale, V. P., Habib, H., Chitren, R., Patel, M., Pramanik, K. C., Jonnalagadda, S. C., Challagundla, K. & Pandey, M. K., Jan 1 2020, (Accepted/In press) In: Seminars in Cancer Biology.Research output: Contribution to journal › Review article › peer-review
2 Scopus citations -
Synthesis, in vitro, and in vivo evaluation of novel N-phenylindazolyl diarylureas as potential anti-cancer agents
Solano, L. N., Nelson, G. L., Ronayne, C. T., Jonnalagadda, S., Jonnalagadda, S. K., Kottke, K., Chitren, R., Johnson, J. L., Pandey, M. K., Jonnalagadda, S. C. & Mereddy, V. R., Dec 1 2020, In: Scientific Reports. 10, 1, 17969.Research output: Contribution to journal › Article › peer-review
Open Access -
Synthesis and biological evaluation of arylphosphonium-benzoxaborole conjugates as novel anticancer agents
Jonnalagadda, S. K., Wielenberg, K., Ronayne, C. T., Jonnalagadda, S., Kiprof, P., Jonnalagadda, S. C. & Mereddy, V. R., Jul 15 2020, In: Bioorganic and Medicinal Chemistry Letters. 30, 14, 127259.Research output: Contribution to journal › Article › peer-review
-
Strictinin, a novel ROR1-inhibitor, represses triple negative breast cancer survival and migration via modulation of PI3K/AKT/GSK3ß activity
Fultang, N., Illendula, A., Chen, B., Wu, C., Jonnalagadda, S., Baird, N., Klase, Z. & Peethambaran, B., May 2019, In: PloS one. 14, 5, e0217789.Research output: Contribution to journal › Article › peer-review
Open Access9 Scopus citations